Navigation Links
Intellikine Completes $51 Million Financing
Date:7/8/2009

LA JOLLA, Calif., July 8 /PRNewswire/ -- Intellikine, Inc., a leader in the development of innovative, small molecule drugs for the treatment of cancer, inflammation and autoimmune diseases, announced today that it has raised $51 million in preferred stock financing. Novartis Bioventures Ltd. led the financing in which additional new investors U.S. Venture Partners, Biogen Idec and FinTech Global Capital participated. Markus Goebel, M.D., Ph.D., Managing Director of the Novartis Venture Funds, will join the company's board of directors.

The investment includes a $28.5 million first closing. In addition, the company can access up to another $22.5 million, subject to the performance of certain milestones, which, if triggered, will bring the total amount raised in this round to $51 million. This latest financing comes less than two years after the company was formed with an initial investment of $12.5 million from founding investors Abingworth, CMEA Capital and Sofinnova Ventures, all of whom participated in this latest financing.

Intellikine is developing a portfolio of isoform-selective inhibitors of the phosphatidyinositol-3-kinase (PI3K) pathway for the treatment of cancer, inflammation and autoimmune diseases. The company has discovered multiple classes of proprietary compounds that are potent, selective and druglike inhibitors of PI3K isoforms. The company's most advanced compound, INK128, a selective TORC1/2 inhibitor, has demonstrated efficacy in multiple models of cancer and is expected to enter Phase I clinical studies within twelve months.

"We are delighted to have generated such excitement among both new and existing investors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Intellikine. "This financing gives us the resources necessary to advance our pipeline of PI3K/mTOR inhibitors into clinical development as well as significant flexibility to build strategic partner
'/>"/>

SOURCE Intellikine, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
2. Verenium Completes Amendment to 8% Senior Convertible Notes
3. Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
4. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
5. Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait
6. EFT BioTech Holdings, Inc.s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait
7. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
8. Cordex Completes Production of ATPace(TM) Clinical Trial Material
9. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
10. Brooks Instrument Completes Acquisition of Celerity's Instrumentation Division
11. Sinovac Completes Construction of H1N1 Virus Seed Bank

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... PDL BioPharma, Inc. (PDL...e for the fourth quarter ended December 31, 2009 o...million for the fourth quarter of 2008. Included i... installment payments of $12.5 million from Alexio...as a one-time $1.8 million payment from Genentech ...
(Date:12/1/2009)... 1 To address the emergence of the...ential, a group of individuals and companies annou...ry Association (SynBIA) in Cambridge, Massachusett...vide a forum for individuals and commercial intere...tunities and its challenges, and advocate for its ...
(Date:12/1/2009)...wire/ -- The Burrill Biotech Select Index managed ...ber. The Select,s gain of 4.5 percent mirrored wha...ets with the Dow up 6.5 percent and the NASDAQ up ...inal two trading days of the month despite investo...ping and Dubai,s reported debt woes. ,, Almost ...
(Date:12/1/2009)...RNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC...l present at the LD MICRO Conference on Thursday, ...tel in Los Angeles. Aethlon Medical,s Chairman and...rview and will provide an update on the company,s ...rifier®, a first-in-class artificial adjunct ...
Breaking Biology Technology:PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2Biotech Gets Back on Track in November 2Biotech Gets Back on Track in November 3Biotech Gets Back on Track in November 4Aethlon Medical to Present at LD MICRO Conference on December 3, 2009 2
...er-year to $2.3 million or 11 cents per ...g, China, Nov. 15 /Xinhua-PRNewswire-FirstCall/ --... ("CBP", "the Company"),one of the leading plasma-...ublic of China ("PRC"), today reported record fina...mber 30, 2007. Third Quarter 2007 Highlights, --...
...ss, publisher of the,journal STEM CELLS(R), has na...editors. Curt I. Civin, current STEM CELLS Editor...h in areas of the journal,s most significant metri...number of manuscripts,submitted. During his tenure...ee outgoing senior editors: Alan M. Gewirtz, Rober...
...ging,Diagnostic Systems, Inc., (OTC Bulletin Board...maging systems, announced that its CT Laser,Mammog...x-ray systems to,detect breast cancer, and its fut... story in the September 17, 2007 issue of RT Image...ric Milne, MD, FRCR, FRCP, IMDS Director,of Clinic...
Other Biology Technology:China Biologic Products Reports Record Third Quarter 2007 Results 2China Biologic Products Reports Record Third Quarter 2007 Results 3China Biologic Products Reports Record Third Quarter 2007 Results 4China Biologic Products Reports Record Third Quarter 2007 Results 5China Biologic Products Reports Record Third Quarter 2007 Results 6China Biologic Products Reports Record Third Quarter 2007 Results 7China Biologic Products Reports Record Third Quarter 2007 Results 8China Biologic Products Reports Record Third Quarter 2007 Results 9China Biologic Products Reports Record Third Quarter 2007 Results 10STEM CELLS Journal Names Co-Editors 2New Optical Breast Cancer Imaging Technology Garners Cover Story in National Radiology Magazine 2New Optical Breast Cancer Imaging Technology Garners Cover Story in National Radiology Magazine 3
(Date:12/1/2009)...eeding strategies. A large proportion of all spec...alist predators feeding on other small animals or ...herbivorous". This is not to say that they only e... of plant-derived matter. For example, some forage...ts, called extra-floral nectar; others feed on the...
(Date:12/1/2009)..., Brown adipose tissue is different from white fa...ure power stations which among other things can ,b...voltage similar to that of a battery, which then p...e mitochondria of brown fat cells have a short cir...nergy released when the fat is broken down is rele...
(Date:12/1/2009)...harks can be solved with a new technique that iden...n their victims, according to a University of Flor...nalogous to analyzing human fingerprints, scientis... shark bites to the jaws and teeth of the powerful...nternational Shark Attack File, which is housed at...
Breaking Biology News(10 mins):Bacterial gut symbionts are tightly linked with the evolution of herbivory in ants 2Brown fat cells make 'spare tires' shrink 2New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3Neuroimaging provides insights into new treatment options for Alzheimers disease 61064 1NHLBI publishes new heart healthy cookbook 61061 1NHLBI publishes new heart healthy cookbook 61061 2David A Asch M D M B A receives AAMC Distinguished Teacher Award 61058 1David A Asch M D M B A receives AAMC Distinguished Teacher Award 61058 2
...done with laboratory rats suggest that supplementa...ant effect in lowering triglycerides, which along ... of the key risk factors in cardiovascular disease...d lowered triglyceride levels up to 60 percent. If...yet clear that would be a greater impact than fou...
... to smell the coffee and enjoy a cup of it befor... your juices flowing. It might keep you going for ...r competitive cyclist, University of Illinois kine... routinely met his teammates at a coffee shop to f...n long-distance training rides. , "The notion was...
...the genetic condition known as phenylketonuria (PK...ually no protein, and instead get their daily dose...sting formula of amino acids. Yet drink it they mu...s them at risk of developing permanent neurologica...etter option may become available. , In April, a...
Other Biology News:New approach discovered to lowering triglycerides 2New approach discovered to lowering triglycerides 3A little java makes it easier to jive, researcher says 2A little java makes it easier to jive, researcher says 3A little java makes it easier to jive, researcher says 4UW-Madison study reveals new options for people with PKU 2UW-Madison study reveals new options for people with PKU 3
...n combination with the corresponding optimized pro...eofector Kits are only functional in combination w...s can be transfected with this kit. The correspond...kets in percent (Efficiency [%] / viability [%]). ...
The National Collection of Pathogenic Viruses (NCPV) from European Collection of Cell Cultures (ECACC)
Rabbit Anti-B-FABP (FL-132) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
...purified preparation of the catalytic subunit of b...izes the identical cleavage site as the native enz...ctivity (1). Novagen&'s enzyme is produced in E. c...ilable, and is qualified for specific cleavage of ...
Biology Products: